KRAS and colorectal cancer: In contrast, in Tunisian population, simultaneous presence of KRAS and TP53 mutations were detected in only 4% of tumor.14 Colorectal cancer patients harboring both KRAS mutations and high TP53 expression exhibit a significantly poorer prognosis.13